Pre-Market Earnings Report for October 30, 2025 : LLY, MA, MRK, SPGI, CMCSA, MO, SO, TT, ICE, BMY, RBLX, CI

A range of companies, including Eli Lilly (LLY), Mastercard (MA), and Merck (MRK), are slated to report Q3 2025 earnings on October 30, 2025, with consensus forecasts showing mixed performance. Eli Lilly is projected for a substantial 410.17% year-over-year EPS increase, while MA, S&P Global (SPGI), and Trane Technologies (TT) are anticipated to exhibit higher growth than industry peers based on their 2025 P/E ratios. Conversely, Comcast (CMCSA), Bristol-Myers Squibb (BMY), and Roblox (RBLX) are forecast to experience year-over-year EPS declines, with Roblox expecting a significant 43.24% decrease. Many of these firms, such as MA and MRK, have consistently beaten analyst expectations in the past year, though Southern Company (SO) and Cigna (CI) each recorded a miss in Q4 2024.

Analysis

A significant cohort of companies, including Eli Lilly (LLY), Mastercard (MA), and Merck (MRK), are slated to report Q3 2025 earnings on October 30, 2025. Eli Lilly stands out with a consensus EPS forecast of $6.02, representing a substantial 410.17% year-over-year increase, while its 2025 P/E of 36.08 against an industry average of 14.60 suggests robust future growth expectations. Mastercard and S&P Global (SPGI) also project strong growth, with P/E ratios significantly above their respective industry averages, implying higher anticipated earnings expansion.

Conversely, several firms face projected year-over-year EPS declines, notably Roblox (RBLX) with a forecast of $-0.53, marking a 43.24% decrease, and Bristol-Myers Squibb (BMY) expecting a 16.11% reduction to $1.51. Comcast (CMCSA) is also forecast for a slight EPS decrease of 1.79% to $1.10. These companies present a more challenging outlook based on current analyst consensus.

Historical performance indicates a strong tendency for many of these companies to beat expectations, with MA, MRK, SPGI, CMCSA, MO, TT, BMY, and RBLX having beaten consensus every quarter in the past year. However, Southern Company (SO) and Cigna (CI) each recorded a miss in Q4 2024, by -1.96% and -15.2% respectively, suggesting potential volatility around their upcoming reports despite positive EPS growth forecasts for Q3 2025.

The P/E ratios provide further context, with LLY, MA, SPGI, SO, TT, and BMY trading at premiums or implying higher growth than their industry peers. In contrast, MRK, CMCSA, MO, ICE, and CI trade at P/E ratios below or near their industry averages, potentially indicating lower growth expectations or a more conservative valuation by the market.

Key Decisions for Investors

• Investors should prioritize monitoring Eli Lilly's actual earnings given its extraordinary projected growth and premium valuation.
• Consider companies like Mastercard, Merck, S&P Global, and Trane Technologies for potential continued outperformance, as they have consistently beaten expectations and many imply higher growth than peers.
• Exercise caution and conduct deeper due diligence on Roblox, Bristol-Myers Squibb, and Comcast due to anticipated EPS declines, and pay close attention to Southern Company and Cigna's reports following their recent earnings misses.